- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/42 - Oxazoles
Patent holdings for IPC class A61K 31/42
Total number of patents in this class: 2004
10-year publication summary
|
144
|
151
|
144
|
104
|
139
|
132
|
128
|
84
|
95
|
4
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Theravance Biopharma R&D IP, LLC | 517 |
45 |
| Intervet Inc. | 871 |
44 |
| Novartis AG | 11297 |
27 |
| Bristol-myers Squibb Company | 4886 |
27 |
| Intervet International B.V. | 1282 |
26 |
| Merck Sharp & Dohme Corp. | 2218 |
23 |
| Boehringer Ingelheim International GmbH | 4762 |
23 |
| The Regents of the University of California | 19479 |
20 |
| Amira Pharmaceuticals, Inc. | 70 |
19 |
| Boehringer Ingelheim Animal Health USA Inc. | 495 |
19 |
| Gilead Sciences, Inc. | 1949 |
18 |
| Pharnext | 95 |
17 |
| Glytech, LLC | 16 |
16 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3353 |
16 |
| Takeda Pharmaceutical Company Limited | 2945 |
15 |
| Proteostasis Therapeutics, Inc. | 72 |
15 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2827 |
15 |
| Merck Sharp & Dohme LLC | 3742 |
15 |
| Amgen Inc. | 3894 |
14 |
| Enanta Pharmaceuticals, Inc. | 422 |
14 |
| Other owners | 1576 |